Novartis International AG http://www.novartis.com Novartis delivers excellent performance in third quarter: recently launched products generate 20%* of sales; Gilenya approved; Alcon consolidated 2010-10-21T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1453762.shtml Novartis receives approval in China for Rasilez, a first-in-class direct renin inhibitor for high blood pressure, the leading preventable cause of death in China 2010-07-20T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1432666.shtml Ranibizumab significantly more effective than standard of care in treating vision loss due to DME, a serious complication of diabetes 2010-05-22T16:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1418121.shtml NAVIGATOR shows valsartan delayed progression to type 2 diabetes in at-risk cardiovascular patients with impaired glucose tolerance 2010-03-14T13:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1393715.shtml Three new Novartis medicines approved in Japan for patients with type 2 diabetes, high blood pressure and advanced kidney cancer 2010-01-20T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1375090.shtml Novartis completes shipment of US supply of Fluvirin® seasonal influenza vaccine 2009-10-06T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1345850.shtml About seasonal influenza Novartis begins shipment of Fluvirin® seasonal influenza vaccine for the U.S. market ahead of schedule 2009-08-05T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1332676.shtml Basel, August 5, 2009 - Novartis Vaccines has started shipping seasonal influenza vaccine to U.S. healthcare facilities for the 2009-2010 season. The company delivered Fluvirin® influenza virus vaccine, which has been approved by the U.S. Food and Drug Administration (FDA), to the U.S. weeks ahead of schedule in anticipation of the increased demand for seasonal influenza vaccine created by the current global (A) H1N1 influenza pandemic. Japanese Ministry of Health approves Rasilez®, a first-in-class direct renin inhibitor (DRI), for the treatment of high blood pressure 2009-07-08T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1327640.shtml Basel, July 8, 2009 - Rasilez® (aliskiren), the first new type of high blood pressure medicine in more than a decade, has been approved for use in Japan. Rasilez directly inhibits renin[9], an enzyme that triggers a process leading to high blood pressure and organ damage. The Ministry of Health, Labour and Welfare (MHLW) in Japan approved Rasilez for the treatment of high blood pressure alone or in combination with other high blood pressure medicines. Rasilez®, first-in-class direct renin inhibitor, provides greater reduction in high blood pressure than ACE inhibitor ramipril in patients 65 and older 2008-11-11T17:30:00 CET http://www.novartis.com/newsroom/media-releases/en/2008/1268561.shtml Basel, November 11, 2008 - New clinical data presented today show first-in-class direct renin inhibitor Rasilez® [*] (aliskiren), known as Tekturna® in the US, provides significantly greater blood pressure reductions in patients with high blood pressure aged 65 and over, compared to the angiotensin-converting enzyme (ACE) inhibitor ramipril[1]. Novartis erzielt im dritten Quartal eine hervorragende Performance: Die jüngsten Produkte steuern 20%* zum Umsatz bei; Gilenya wird zugelassen; Alcon wird konsolidiert 2010-10-21T07:00:00+01:00 http://www.novartis.com/newsroom/media-releases/de/2010/1453748.shtml Novartis erhält die Zulassung der FDA für Gilenya(TM) - eine neue Primärtherapie für Multiple Sklerose, welche die Schubhäufigkeit und Gefahr von Folgeschäden deutlich reduziert 2010-09-22T07:00:00 CET http://www.novartis.com/newsroom/media-releases/de/2010/1446868.shtml Gestützt auf eine verstärkte Innovationsdynamik erzielt Novartis im zweiten Quartal eine starke finanzielle Performance 2010-07-15T07:00:00+01:00 http://www.novartis.com/newsroom/media-releases/de/2010/1431807.shtml Das Gesundheitsportfolio von Novartis erzielt im ersten Quartal 2010 starke Zuwächse - mit Fortschritten bei Innovation, Wachstum und Produktivität 2010-04-20T07:00:00+01:00 http://www.novartis.com/newsroom/media-releases/de/2010/1405500.shtml Novartis erzielt 2009 Rekordergebnisse - Neu eingeführte Produkte erweisen sich als Wachstumstreiber 2010-01-26T07:00:00+01:00 http://www.novartis.com/newsroom/media-releases/de/2010/1377020.shtml Novartis verzeichnet in den ersten neun Monaten 2009 eine kräftige Dynamik der neuen Produkte und erzielt eine starke operative Performance 2009-10-22T06:59:00+01:00 http://www.novartis.com/newsroom/media-releases/de/2009/1349244.shtml Neun Monate bis 30. September Novartis erzielt im ersten Halbjahr 2009 eine starke operative Performance - dank der anhaltenden Innovationskraft der Division Pharmaceuticals 2009-07-16T06:59:00+01:00 http://www.novartis.com/newsroom/media-releases/de/2009/1329092.shtml Erstes Halbjahr Novartis verzeichnet im ersten Quartal 2009 eine starke Expansion der Division Pharmaceuticals und setzt die Verjüngung des Produktportfolios fort 2009-04-23T06:59:00+01:00 http://www.novartis.com/newsroom/media-releases/de/2009/1329173.shtml